Research Topics
Genomes and Genes | Herman BurgerSummaryAffiliation: Erasmus MC Country: The Netherlands Publications
| Collaborators
|
Detail Information
Publications
Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genesHerman Burger
Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute, Rotterdam, The Netherlands
Cancer Biol Ther 4:1270-4. 2005..The latter may imply that these wild-type c-KIT and PDGFR tumor types will probably not benefit from imatinib treatment...
Drug transporters of platinum-based anticancer agents and their clinical significanceHerman Burger
Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Drug Resist Updat 14:22-34. 2011..In addition, transporter-mediated tumour resistance, the impact of potential platinum transporter-mediated drug-drug interactions, and the role of drug transporters in the renal elimination of platinum compounds are discussed...- Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pumpHerman Burger
Department of Medical Oncology, Erasmus Medical Center Rotterdam, Daniel den Hoed Kliniek Josephine Nefkens Institute, Rotterdam, The Netherlands
Blood 104:2940-2. 2004..Since BCRP is highly expressed in the gastrointestinal tract, BCRP might not only play a role in cellular resistance of tumor cells but also influence the gastrointestinal absorption of imatinib... - Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimensH Burger
Department of Medical Oncology, Erasmus MC, Josephine Nefkens Building Room Be420, PO Box 1738, 3000 DR Rotterdam, The Netherlands
Eur J Cancer 39:793-9. 2003..Apparently, c-KIT oncoprotein expression in SCLC was not correlated with activating mutations in c-kit exon 11. In analogy to GISTs, our results could imply that SCLC patients would not benefit from treatment with STI571... 
Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)H Burger
Department of Medical Oncology, Erasmus Medical Center Rotterdam Josephine Nefkens Institute and Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Br J Pharmacol 159:898-908. 2010..As decreased drug accumulation is a key mechanism of platinum resistance, SLCs may also contribute to the development of resistance. Here, we define the role of hSLC22A2 (OCT2) in the cellular uptake of platinum compounds...- Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumpsHerman Burger
Department of Medical Oncology, Erasmus Medical Center Rotterdam-Josephine Nefkens Institute, Rotterdam, The Netherlands
Cancer Biol Ther 4:747-52. 2005.... - Anticancer drug resistance induced by disruption of the Saccharomyces cerevisiae NPR2 gene: a novel component involved in cisplatin- and doxorubicin-provoked cell killPaul W Schenk
Department of Medical Oncology, Erasmus University Medical Center Rotterdam, Josephine Nefkens Building room Be422, P O Box 1738, 3000 DR Rotterdam, The Netherlands
Mol Pharmacol 64:259-68. 2003.... - Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporterJozien Helleman
Department of Medical Oncology, Erasmus MC/Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Cancer Biol Ther 5:943-9. 2006..In conclusion, we generated an A2780 subline that showed a uniquely stable platinum resistance phenotype, which could theoretically be caused by an impaired inward transporter specific for cis-configurated platinum compounds... - Drug transporters and imatinib treatment: implications for clinical practiceKarel Eechoute
Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center, Rotterdam, The Netherlands
Clin Cancer Res 17:406-15. 2011..In addition, more pharmacogenetic studies will be needed to validate associations... - RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic responseHerman Burger
Department of Medical Oncology, Erasmus Medical Center Rotterdam Daniel den Hoed Kliniek Josephine Nefkens Institute, 3000 DR Rotterdam, The Netherlands
Clin Cancer Res 9:827-36. 2003..The aim of this study was to investigate whether expression of particular drug resistance genes in primary operable breast cancer correlates with response to first-line chemotherapy in advanced disease... - Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinibHerman Burger
Department of Medical Oncology, Erasmus Medical Center Rotterdam, The Netherlands
Cell Cycle 3:1502-5. 2004..Our findings may have serious implications for the chronic imatinib treatment of cancer patients... - Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulationMaja J A de Jonge
Erasmus University Medical Center Daniel den Hoed Cancer Center, Department of Medical Oncology, Rotterdam, The Netherlands
Eur J Cancer 46:3016-21. 2010..v.) LiPlaCis. and to assess plasma and urine pharmacokinetics and plasma biomarkers... - Inactivation of the Saccharomyces cerevisiae SKY1 gene induces a specific modification of the yeast anticancer drug sensitivity profile accompanied by a mutator phenotypePaul W Schenk
Department of Medical Oncology, University Hospital Rotterdam-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
Mol Pharmacol 61:659-66. 2002..Disruption of the S. cerevisiae SKY1 gene would thus result in deregulation of such mechanisms and, consequently, lead to altered drug sensitivity... - Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumorsFerry A L M Eskens
Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
Clin Cancer Res 17:7156-63. 2011..To assess the maximum tolerated dose (MTD)/dose-limiting toxicities (DLT), safety, pharmacokinetics, and pharmacodynamics of tivozanib, a potent and selective oral VEGF receptor (VEGFR) tyrosine kinase inhibitor... - Effect of ABCG2 genotype on the oral bioavailability of topotecanAlex Sparreboom
Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland, USA
Cancer Biol Ther 4:650-8. 2005..0% versus 31.4%; p = 0.037). It is suggested that the high frequency of the A allele in certain ethnic groups may have therapeutic implications for individuals treated with topotecan or other ABCG2 substrates... - A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumoursF A L M Eskens
Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, The Netherlands
Br J Cancer 98:80-5. 2008..No partial or complete responses were observed, stable disease lasting more than four cycles was seen in seven patients. The recommended dose for studies with BIBW 2992 for 14 days followed by 14 days off medication is 70 mg OD... - Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumoursI R H M Konings
Department of Medical Oncology, Erasmus University Medical Center, Room HE 118, P O Box 2040, Rotterdam 3000 CA, The Netherlands
Br J Cancer 103:987-92. 2010..This phase I, accelerated titration study assessed maximum tolerated dose, safety, pharmacokinetics and pharmacodynamic effects of JNJ-26483327... - SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell lineP W Schenk
Department of Medical Oncology, University Hospital Rotterdam Daniel den Hoed Cancer Center, Josephine Nefkens Institute, 3000 DR Rotterdam, The Netherlands
Cancer Res 61:6982-6. 2001..Our new findings strongly suggest that SRPK1 is involved in cisplatin-induced cell kill and indicate that SRPK1 might potentially be of importance for studying clinical drug resistance... - Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell lineK Nooter
Department of Medical Oncology, University Hospital Rotterdam, The Netherlands
Br J Cancer 71:556-61. 1995.... - Interleukin-3 treatment of rhesus monkeys leads to increased production of histamine-releasing cells that express interleukin-3 receptors at high levelsF C van Gils
Department of Hematology, Erasmus University, Rotterdam, The Netherlands
Blood 86:592-7. 1995..It also indicates that IL-3, in addition to its direct effects on hematopoietic cells, may also stimulate hematopoiesis through the release of secondary mediators such as histamine by IL-3-responsive mature cells... - The spliceosome as target for anticancer treatmentR J van Alphen
Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands
Br J Cancer 100:228-32. 2009..Alternative) Splicing events may play an essential role in tumourigenesis. The recent discovery that the spliceosome is a target for novel compounds with anticancer activity opens up new therapeutic avenues... - Vitamin D receptor genotype is associated with radiographic osteoarthritis at the kneeA G Uitterlinden
Department of Internal Medicine III, Erasmus University Medical School, 3000 DR Rotterdam, The Netherlands
J Clin Invest 100:259-63. 1997..e., the collagen type IIa1 gene encoding the most abundant protein in cartilage, might contribute to the association... - Molecular evolution of interleukin-3H Burger
Department of Medical Oncology, Dr Daniel den Hoed Cancer Center Dijkzigt, University Hospital Rotterdam, The Netherlands
J Mol Evol 39:255-67. 1994..3 cell-surface receptor. Insight into IL-3 architecture and structural analysis of the IL-3 receptor are needed to analyze the unusually fast evolution of IL-3 in more detail... - Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell linesH Burger
Department of Medical Oncology, University Hospital Rotterdam and Rotterdam Cancer Institute Daniel den Hoed Kliniek, The Netherlands
Br J Cancer 77:1562-7. 1998.... - Interaction of imatinib with human organic ion carriersShuiying Hu
Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphia, TN 38105, USA
Clin Cancer Res 14:3141-8. 2008..Here, we characterized the contribution of solute carriers to imatinib transport in an effort to further understand mechanisms involved in the intracellular uptake and retention (IUR) of the drug... - Association of enzyme and transporter genotypes with the pharmacokinetics of imatinibErin R Gardner
Clinical Pharmacology Research Core, SAIC-Frederick, Frederick, USA
Clin Pharmacol Ther 80:192-201. 2006..Further investigation is required to quantitatively assess the clinical significance of homozygous variant ABCG2 and CYP2D6 genotypes in patients treated with imatinib...